Moleculin Biotech CS (MBRX) Stock Price, Quote & News

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology

Sector: Healthcare

Phone: (713) 300-5160

Website: moleculin.com

Address:

5300 Memorial Drive, Suite 950, Houston, United States

jkgyuool Oct. 5 at 12:44 AM

$MBRX once this news come out, I think we will have a better idea of direction imo. Hopefully within 2 months

0 · Reply

IVALTE Oct. 4 at 9:16 PM

$MBRX Next to be deslisted

1 · Reply

jkgyuool Oct. 3 at 9:39 PM

$MBRX again, I don’t trust management and the deals they make. Until this PoS is bought or partnership, then I will be more positive. This will take the full control out of this leadership team that has taken bonuses and major base salaries for years while investors like me are losing big. Karma is a bitch fortunately. Hopefully the culprit(s) will have their day in court or on judgement day.

0 · Reply

jkgyuool Oct. 3 at 9:33 PM

$MBRX the same scam artist is back 👇🏽👇🏽👇🏽

0 · Reply

CrisMars Oct. 3 at 9:04 PM

$MBRX most everyone here is waiting for a news lift. I was too. i reduced big time….and remain watchful… whoever holds the 65M warrants can sell short down to .34 and conceivably cover with a warrant exercise and still stay below the 4.9% or 9.9% limits.

0 · Reply

CrisMars Oct. 3 at 8:59 PM

$MBRX The vote was for registration of 65M warrants at 0.53 but the registration statement says 0.34. i was long and strong in this now i am disappointed. i do not see how they can avoid a massive RS…not happy.

0 · Reply

IVALTE Oct. 3 at 6:20 PM

$MBRX the same again and again

0 · Reply

J_machete Oct. 3 at 5:28 PM

$MBRX why down so much?

0 · Reply

jkgyuool Oct. 3 at 5:28 PM

$MBRX shady shady

0 · Reply

Waja215 Oct. 3 at 5:27 PM

$MBRX

0 · Reply

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 9, 2025, 8:45 AM EDT - 25 days ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 8, 2025, 8:30 AM EDT - 26 days ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Aug 28, 2025, 8:30 AM EDT - 5 weeks ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 27, 2025, 8:45 AM EDT - 5 weeks ago

Moleculin Issues New Positive AML Overall Survival Data:

Aug 14, 2025, 9:15 AM EDT - 7 weeks ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 8:05 AM EDT - 7 weeks ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 6, 2025, 8:40 AM EDT - 2 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Jul 30, 2025, 8:35 AM EDT - 2 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 22, 2025, 8:45 AM EDT - 2 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 17, 2025, 8:25 AM EDT - 2 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 9, 2025, 8:35 AM EDT - 3 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jun 20, 2025, 9:20 AM EDT - 3 months ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 3 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 3 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 5, 2025, 8:00 AM EDT - 4 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 4 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

May 14, 2025, 12:20 PM EDT - 5 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 5 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:40 AM EDT - 5 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 7, 2025, 9:00 AM EDT - 5 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 6, 2025, 9:00 AM EDT - 5 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 5, 2025, 8:45 AM EDT - 5 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Apr 29, 2025, 8:35 AM EDT - 5 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 17, 2025, 8:30 AM EDT - 6 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 1, 2025, 8:30 AM EDT - 6 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Mar 24, 2025, 10:50 AM EDT - 6 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 7:05 AM EDT - 6 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 8:05 AM EDT - 7 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 11, 2025, 8:45 AM EDT - 7 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 10, 2025, 8:45 AM EDT - 7 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Mar 6, 2025, 8:30 AM EST - 7 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 3, 2025, 8:30 AM EST - 7 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Feb 25, 2025, 12:35 PM EST - 7 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 13, 2025, 1:19 PM EST - 8 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:05 PM EST - 8 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 9:25 AM EST - 8 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 11, 2025, 8:40 AM EST - 8 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Jan 27, 2025, 8:30 AM EST - 8 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 8, 2025, 8:30 AM EST - 9 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Dec 11, 2024, 8:00 AM EST - 10 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Nov 18, 2024, 8:15 AM EST - 11 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 14, 2024, 8:15 AM EST - 11 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 12, 2024, 8:00 AM EST - 11 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 11, 2024, 11:17 AM EST - 11 months ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:05 AM EST - 11 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 9:00 AM EST - 11 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 4, 2024, 8:30 AM EST - 11 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Oct 17, 2024, 8:40 AM EDT - 1 year ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

jkgyuool Oct. 5 at 12:44 AM

$MBRX once this news come out, I think we will have a better idea of direction imo. Hopefully within 2 months

0 · Reply

IVALTE Oct. 4 at 9:16 PM

$MBRX Next to be deslisted

1 · Reply

jkgyuool Oct. 3 at 9:39 PM

0 · Reply

jkgyuool Oct. 3 at 9:33 PM

$MBRX the same scam artist is back 👇🏽👇🏽👇🏽

0 · Reply

CrisMars Oct. 3 at 9:04 PM

0 · Reply

CrisMars Oct. 3 at 8:59 PM

0 · Reply

IVALTE Oct. 3 at 6:20 PM

$MBRX the same again and again

0 · Reply

J_machete Oct. 3 at 5:28 PM

$MBRX why down so much?

0 · Reply

jkgyuool Oct. 3 at 5:28 PM

$MBRX shady shady

0 · Reply

Waja215 Oct. 3 at 5:27 PM

$MBRX

0 · Reply

IVALTE Oct. 2 at 8:42 PM

$MBRX dedicated all of you that think this one can reach $1, $2, $4...

1 · Reply

jkgyuool Oct. 2 at 6:19 PM

let me guess. Someone is gonna come out and say this is all profit taking. This is all shady trading in my opinion.$MBRX

0 · Reply

AppleJuice14 Oct. 2 at 1:49 PM

$MBRX she’ll bounce back to 0.55 by EoD Friday 😌

0 · Reply

IVALTE Oct. 2 at 1:32 PM

$MBRX a new day but the same tendency

0 · Reply

carls0306 Oct. 1 at 6:58 PM

$MBRX

0 · Reply

SPYmyQQQ Oct. 1 at 5:01 PM

💊 🚀 $MBRX up ⬆️42.87% since our entry $0.3858 on Sep 18, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!

0 · Reply

Zdxss1 Oct. 1 at 2:49 PM

$MBRX This rise in the stock price indicates the end of the period of dividing the cake between them.

1 · Reply

Harry786N Oct. 1 at 1:56 PM

$MBRX $20 million market cap. Give me a break. This should be atleast a $10 stock!!

1 · Reply

PutLong Oct. 1 at 12:34 PM

Let's get bullish! $MBRX this is looking real good $ADAP why's it so quiet in here?

0 · Reply

OnTargetCapital Oct. 1 at 12:07 PM

$MBRX Nice move over the last couple of weeks. Sub 0.4 to .55. Filling the latest gap. Most recent analyst target @ 4.00. Need the vol to continue to build off this recent move. $RZLV $CJET

0 · Reply

CrisMars Oct. 1 at 2:42 AM

$MBRX this site, Stocktwits, by and through its insiders shorted MBRX. They bash it here. I’ve been watching the stocktwits shills for 6 months bash and lie. it’s really pathetic, dem type deception and lies…weak men and stinky women probably...lol

1 · Reply

TradingBeasts Oct. 1 at 12:09 AM

$MBRX swinging

0 · Reply

Market Cap	24.75M
Revenue (ttm)	0.00
Net Income (ttm)	-21.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,068,300
Avg Vol	3,658,666
Day's Range	N/A - N/A
Shares Out	49.50M
Stochastic %K	37%
Beta	1.59
Analysts	Strong Sell
Price Target	$6.67